CD274 and hepatocellular carcinoma: This study reported for the first time that higher serum anti-PD-1 AAb levels in patients with HCC correlated with a poorer prognosis, which may serve as a potential biomarker for OS when using anti-PD-L1 therapy as the first-line treatment against HCC.